Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycolic Acid SCHEMBL2518351 | 1.00 | LMNA (0.50) | LMNAOR51E2LDHASRRALKBH5 | |
| Glycolic Acid SCHEMBL1222 | 1.00 | — | — | |
| Glycolic Acid SCHEMBL1331333 | 1.00 | — | — | |
| Glycolic Acid SCHEMBL11698763 | 1.00 | LMNA (0.50) | LMNAOR51E2LDHASRRALKBH5 | |
| Glycolic Acid SCHEMBL6362687 | 1.00 | — | — | |
| Glycolic Acid SCHEMBL6813507 | 0.95 | — | — | |
| Glycolic Acid SCHEMBL1002391 | 0.95 | — | — | |
| Glycolic Acid SCHEMBL10878582 | 0.95 | — | — | |
| Glycolic Acid SCHEMBL5074103 | 0.95 | — | — | |
| Glycolic Acid SCHEMBL726844 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554263-B1 | COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| WO-2004089357-A2 | ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2004-10-21 | — | — | WO | claimed |
| US-5281655-A | Hydroxy- or carboxy-containing acrylic resins, alkyd resins, epoxy resins, fluorine-containing resins, urethane resins, crosslinking agent | KANSAI PAINT COMPANY, LIMITED (JP) | 1994-01-25 | — | — | US | claimed |
| JP-4103680-A | — | — | None | — | — | JP | disclosed |
| JP-4198361-A | — | — | None | — | — | JP | disclosed |
| JP-7053916-A | — | — | None | — | — | JP | disclosed |
| US-20260078416-A1 | ORTHOGONAL METABOLIC FRAMEWORK FOR ONE-CARBON UTILIZATION | MOJIA BIOTECH PTE LTD (SG) | 2026-03-19 | — | — | US | disclosed |
| US-20260014120-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE | NeuviDerm LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250369024-A1 | Acyloin Condensation Reactions, Enzymes, and Products Thereof | MOJIA BIOTECH PTE LTD (SG) | 2025-12-04 | — | — | US | disclosed |
| EP-4649157-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | Mojia Biotech Pte. Ltd. (SG) | 2025-11-19 | — | — | EP | disclosed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-5281655-A | Hydroxy- or carboxy-containing acrylic resins, alkyd resins, epoxy resins, fluorine-containing resins, urethane resins, crosslinking agent | KANSAI PAINT COMPANY, LIMITED (JP) | 1994-01-25 | — | — | US | disclosed |
| US-5248761-A | Amino acid terminated polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-09-28 | — | — | US | disclosed |
| US-5227422-A | Water soluble resin, polyurethane, crosslinking agent, clear coating, one-step baking | KANSAI PAINT COMPANY, LIMITED (JP) | 1993-07-13 | — | — | US | disclosed |
| US-5227422-A | Water soluble resin, polyurethane, crosslinking agent, clear coating, one-step baking | KANSAI PAINT COMPANY, LIMITED (JP) | 1993-07-13 | — | — | US | disclosed |
| JP-H04198361-A | LOW-TEMPERATURE CURABLE COMPOSITION | SANYO CHEM IND LTD | 1992-07-17 | — | — | JP | disclosed |
| JP-H04103680-A | WATER-BASED COATING MATERIAL AND COATING METHOD USING THE SAME | KANSAI PAINT CO LTD | 1992-04-06 | — | — | JP | disclosed |
| US-5086110-A | From 1,12-Dodecanediisocyanate, dimethylolacetic acid or homologue thereof, and polymeric glycol | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-02-04 | — | — | US | disclosed |
| US-4264573-A | TABLETS CONTAINING LITHIUM CARBONATE AS THE ACTIVE INGREDIENT HAS SLOW IN VIVO RELEASE | ROWELL LABORATORIES, INC. (US) | 1981-04-28 | — | — | US | disclosed |
| US-4183836-A | TERTIARY AMINE CHAIN EXTENDED POLYMER COATING | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078416-A1 | ORTHOGONAL METABOLIC FRAMEWORK FOR ONE-CARBON UTILIZATION | COASY, HACL2, ACSL1 | LMNA 3463/4885OR51E2 978/4885LDHA 409/4885 |
| US-20260014120-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE | CRAT, CCR10, SLC25A20 | LMNA 4002/4885OR51E2 4365/4885LDHA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.